Deudextromethorphan - Avanir Pharmaceuticals
Alternative Names: AVP-786; CTP-786; d-DM; Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]; Deuterated dextromethorphan plus ultra low dose quinidine; Deuterated DM plus ultra low dose quinidine; Deuterated-dextromethorphan; Deuterated-DMLatest Information Update: 30 May 2024
At a glance
- Originator Concert Pharmaceuticals
- Developer Avanir Pharmaceuticals
- Class Antidepressants; Antipsychotics; Antitussives; Behavioural disorder therapies; Morphinans; Neuroprotectants; Opioid analgesics; Organic deuterium compounds; Small molecules
- Mechanism of Action Cytochrome P-450 enzyme system inhibitors; KATP channel inhibitors; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Agitation
- Phase II/III Schizophrenia
- Phase II Impulse control disorders; Major depressive disorder; Neurodegenerative disorders
- No development reported Neuropathic pain; Psychiatric disorders
Most Recent Events
- 22 May 2024 Otsuka Pharmaceutical terminates development of Deudextromethorphan
- 12 Feb 2024 Efficacy and adverse event data from a phase III trial in Agitation released by Otsuka Pharmaceutical
- 14 Dec 2023 Otsuka Pharmaceutical Development & Commercialization completes a phase III trial in Agitation in USA, Australia, Hungary, Italy, Poland, France, South Africa, Czech Republic, Bulgaria, Spain and the UK (PO) (NCT03393520)